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Abstract
Medical practitioners use survival models to explore and understand the rela-
tionships between patients’ covariates (e.g. clinical and genetic features) and
the effectiveness of various treatment options. Standard survival models like the
linear Cox proportional hazards model require extensive feature engineering or
prior medical knowledge to model treatment interaction at an individual level.
While nonlinear survival methods, such as neural networks and survival forests,
can inherently model these high-level interaction terms, they have yet to be shown
as effective treatment recommender systems. We introduce DeepSurv, a Cox
proportional hazards deep neural network and state-of-the-art survival method for
modeling interactions between a patient’s covariates and treatment effectiveness
in order to provide personalized treatment recommendations. We perform
a number of experiments training DeepSurv on simulated and real survival
data. We demonstrate that DeepSurv performs as well as or better than other
state-of-the-art survival models and validate that DeepSurv successfully models
increasingly complex relationships between a patient’s covariates and their risk of
failure. We then show how DeepSurv models the relationship between a patient’s
features and effectiveness of different treatment options to show how DeepSurv
can be used to provide individual treatment recommendations. Finally, we train
DeepSurv on real clinical studies to demonstrate how it’s personalized treatment
recommendations would increase the survival time of a set of patients. The
predictive and modeling capabilities of DeepSurv will enable medical researchers
to use deep neural networks as a tool in their exploration, understanding, and
prediction of the effects of a patient’s characteristics on their risk of failure.
1 Introduction
Medical researchers use survival models to evaluate the significance of prognostic variables in out-
comes such as death or cancer recurrence and subsequently inform patients of their treatment options
[1, 2, 3, 4]. One standard survival model is the Cox proportional hazards model (CPH) [5]. The CPH
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is a semiparametric model that calculates the effects of observed covariates on the risk of an event
occurring (e.g. ‘death’). The model assumes that a patient’s risk of failure is a linear combination
of the patient’s covariates. This assumption is referred to as the linear proportional hazards condi-
tion. However, in many applications, such as providing personalized treatment recommendations, it
may be too simplistic to assume that the risk function is linear. As such, a richer family of survival
models is needed to better fit survival data with nonlinear risk functions.
To model nonlinear survival data, researchers have applied three main types of neural networks to
the problem of survival analysis. These include variants of: (i) classification methods [see details in
6, 7], (ii) time-encoded methods [see details in 8, 9], (iii) and risk-predicting methods [see details
in 10]. This third type is a feed-forward neural network (NN) that estimates an individual’s risk of
failure. In fact, Faraggi-Simon’s network is seen as a nonlinear extension of the Cox proportional
hazards model.
Risk neural networks learn highly complex and nonlinear relationships between prognostic features
and an individual’s risk of failure. In application, for example, when the success of a treatment
option is affected by an individual’s features, the NN learns the relationship without prior feature
selection or domain expertise. The network is then able to provide a personalized recommendation
based on the computed risk of a treatment.
However, previous studies have demonstrated mixed results on NNs ability to predict risk. For
instance, researchers have attempted to apply the Faraggi-Simon network with various extensions,
but they have failed to demonstrate improvements beyond the linear Cox model, see [11], [12] and
[13]. One possible explanation is that the practice of NNs was not as developed as it is today. To
the best of our knowledge, NNs have not outperformed standard methods for survival analysis (e.g.
CPH). Our manuscript shows that this is no longer the case; with modern techniques, risk NNs have
state-of-the-art performance and can be used for a variety of medical applications.
The goals of this paper are: (i) to show that the application of deep learning to survival analysis
performs as well as or better than other survival methods in predicting risk; and (ii) to demonstrate
that the deep neural network can be used as a personalized treatment recommender system and a
useful framework for further medical research.
We propose a modern Cox proportional hazards deep neural network, henceforth referred to as
DeepSurv, as the basis for a treatment recommender system. We make the following contributions.
First, we show that DeepSurv performs as well as or better than other survival analysis methods
on survival data with both linear and nonlinear risk functions. Second, we include an additional
categorical variable representing a patient’s treatment group to illustrate how the network can learn
complex relationships between an individual’s covariates and the effect of a treatment. Our experi-
ments validate that the network successfully models the treatment’s risk within a population. Third,
we use DeepSurv to provide treatment recommendations tailored to a patient’s observed features.
We confirm our results on real clinical studies, which further demonstrates the power of DeepSurv.
Finally, we show that the recommender system supports medical practitioners in providing person-
alized treatment recommendations that potentially could increase the median survival time for a set
of patients.
The organization of the manuscript is as follows: in Section 2, we provide a brief background
on survival analysis. In Section 3, we present our contributions, including an explanation of our
implementation of DeepSurv and our proposed recommender system. In Section 4, we describe the
experimental design and results. Section 5 concludes the manuscript.
2 Background
In this section, we define survival data and the approaches for modeling a population’s survival and
failure rate. Additionally, we discuss linear and nonlinear survival models and their limitations.
2.1 Survival data
Survival data is comprised of three elements: a patient’s baseline data x, a failure event time T ,
and an event indicator E. If an event (e.g. death) is observed, the time interval T corresponds
to the time elapsed between the time in which the baseline data was collected and the time of the
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event occurring, and the event indicator is E = 1. If an event is not observed, the time interval
T corresponds to the time elapsed between the collection of the baseline data and the last contact
with the patient (e.g. end of study), and the event indicator is E = 0. In this case, the patient is
said to be right-censored. If one opts to use standard regression methods, the right-censored data is
considered to be a type of missing data. This is typically discarded which can introduce a bias in
the model. Therefore, modeling right-censored data requires special consideration or the use of a
survival model.
Survival and hazard functions are the two fundamental functions in survival analysis. The survival
function is denoted by S(t) = Pr(T > t), which signifies the probability that an individual has
‘survived’ beyond time t. The hazard function is a measure of risk at time t. A greater hazard
signifies a greater risk of death. The hazard function λ(t) is defined as:
λ(t) = lim
δ→0
Pr(t ≤ T < t+ δ | T ≥ t)
δ
. (1)
A proportional hazards model is a common method for modeling an individual’s survival given
their baseline data x. The model assumes that the hazard function is composed of two functions:
a baseline hazard function, λ0(t), and a risk function, h(x), denoting the effects of an individual’s
covariates. The hazard function is assumed to have the form λ(t|x) = λ0(t) · eh(x).
2.2 Linear Survival Models
The CPH is a proportional hazards model that estimates the risk function h(x) by a linear function
hˆβ(x) = β
Tx. To perform Cox regression, one tunes the weights β to optimize the Cox partial
likelihood. The partial likelihood is the product of the probability at each event time Ti that the
event has occurred to individual i, given the set of individuals still at risk at time Ti. The Cox partial
likelihood is parameterized by β and defined as
Lc(β) =
∏
i:Ei=1
exp(hˆβ(xi))∑
j∈<(Ti)
exp(hˆβ(xj))
, (2)
where the values Ti, Ei, and xi are the respective event time, event indicator, and baseline data for
the ith observation. The product is defined over the set of patients with an observable event Ei = 1.
The risk set <(t) = {i : Ti ≥ t} is the set of patients still at risk of failure at time t.
In many applications, for example modeling nonlinear gene interactions, we cannot assume the
data satisfies the linear proportional hazards condition. In this case, the CPH model would require
computing high-level interaction terms. This becomes prohibitively expensive as the number of
features and interactions increases. Therefore, a more complex nonlinear model is needed.
2.3 Nonlinear survival models
The Faraggi-Simon method is a feed-forward neural network that provides the basis for a nonlinear
proportional hazards model. [10] experimented with a single hidden layer network with two or three
nodes. Their model requires no prior assumption of the risk function h(x) other than continuity.
Instead, the NN computes nonlinear features from the training data and calculates their linear com-
bination to estimate the risk function. Similar to Cox regression, the network optimizes a modified
Cox partial likelihood. They replace the linear combination of features hˆβ(x) in Equation 2 with the
output of the network hˆθ(x).
As previous research suggests, the Faraggi-Simon network has not been shown to outperform the
linear CPH [10, 12, 13]. Furthermore, to the best of our knowledge, we were the first to attempt
applying modern deep learning techniques to the Cox proportional hazards loss function.
Another popular machine learning approach to modeling patients’ risk function is the random sur-
vival forest (RSF) [14, 15]. The random survival forest is a tree method that produces an ensemble
estimate for the cumulative hazard function.
A more recent deep learning approach models the event time according to a Weibull distribution
with parameters given by latent variables generated by a deep exponential family [16].
3
3 Methods
In this section, we describe our methodology for providing personalized treatment recommendations
using DeepSurv. First, we describe the architecture and training details of DeepSurv, an open source
Python module that applies recent deep learning techniques to a nonlinear Cox proportional hazards
network. Second, we define DeepSurv as a prognostic model and show how to use the network’s
predicted risk function to provide personalized treatment recommendations.
3.1 DeepSurv
DeepSurv is a multi-layer perceptron, which predicts a patient’s risk of death. The output of the
network is a single node, which estimates the risk function hˆθ(x) parameterized by the weights of
the network θ. Similar to the Faraggi-Simon network, we set the loss function to be the negative log
partial likelihood of Equation 2:
l(θ) := −
∑
i:Ei=1
(
hˆθ(xi)− log
∑
j∈<(Ti)
ehˆθ(xj)
)
. (3)
We allow a deep architecture (i.e. more than one hidden layer) and apply modern techniques such
as weight decay regularization, Rectified Linear Units (ReLU) [17] with batch normalization [18],
Scaled Exponential Linear Units (SELU) [19], dropout [20], gradient descent optimization algo-
rithms (Stochastic Gradient Descent and Adaptive Moment Estimation (Adam) [21]), Nesterov mo-
mentum [22], gradient clipping [23], and learning rate scheduling [24].
To tune the network’s hyper-parameters, we perform a Random hyper-parameter optimization search
[25]. For more technical details, see Appendix A.
3.2 Treatment recommender system
In a clinical study, patients are subject to different levels of risk based on their relevant prognostic
features and which treatment they undergo. We generalize this assumption as follows. Let all
patients in a given study be assigned to one of n treatment groups τ ∈ {0, 1, ..., n − 1}. We
assume each treatment i to have an independent risk function hi(x). Collectively, the hazard function
becomes:
λ(t;x|τ = i) = λ0(t) · ehi(x). (4)
For any patient, the network should be able to accurately predict the risk hi(x) of being prescribed a
given treatment i. Then, based on the assumption that each individual has the same baseline hazard
function λ0(t), we can take the log of the hazards ratio to calculate the personal risk of prescribing
one treatment option over another. We define this difference of log hazards as the recommender
function or recij(x):
recij(x) = log
( λ(t;x|τ = i)
λ(t;x|τ = j)
)
= log
(λ0(t) · ehi(x)
λ0(t) · ehj(x)
)
= hi(x)− hj(x).
(5)
The recommender function can be used to provide personalized treatment recommendations. We
first pass a patient through the network once in treatment group i and again in treatment group j
and take the difference. When a patient receives a positive recommendation recij(x), treatment i
leads to a higher risk of death than treatment j. Hence, the patient should be prescribed treatment
j. Conversely, a negative recommendation indicates that treatment i is more effective and leads to a
lower risk of death than treatment j, and we recommend treatment i.
DeepSurv’s architecture holds an advantage over the CPH because it calculates the recommender
function without an a priori specification of treatment interaction terms. In contrast, the CPH
model computes a constant recommender function unless treatment interaction terms are added to
the model, see Appendix B for more details. Discovering relevant interaction terms is expensive
because it requires extensive experimentation or prior biological knowledge of treatment outcomes.
Therefore, DeepSurv is more cost-effective compared to CPH.
4
4 Results
We perform four sets of experiments: (i) simulated survival data, (ii) real survival data, (iii) simu-
lated treatment data, and (iv) real treatment data. First, we use simulated data to show how DeepSurv
successfully learns the true risk function of a population. Second, we validate the network’s predic-
tive ability by training DeepSurv on real survival data. Third, we simulate treatment data to verify
that the network models multiple risk functions in a population based on the specific treatment a pa-
tient undergoes. Fourth, we demonstrate how DeepSurv provides treatment recommendations and
show that DeepSurv’s recommendations improve a population’s survival rate. For more technical
details on the experiments, see Appendix A.
In addition to training DeepSurv on each dataset, we run a linear CPH regression for a baseline
comparison. We also fit a RSF to compare DeepSurv against a state-of-the-art nonlinear survival
model. Even though we can compare the RSF’s predictive accuracy to DeepSurv’s, we do not
measure the RSF’s performance on modeling a simulated dataset’s true risk function h(x). This is
due to the fact that the the RSF calculates the cumulative hazard function Λ(t) =
∫ t
0
λ(τ)dτ rather
than the hazard function λ(t).
4.1 Evaluation
Survival data
To evaluate the models’ predictive accuracy on the survival data, we measure the concordance-index
(C-index) c as outlined by [26]. The C-index is the most common metric used in survival analysis
and reflects a measure of how well a model predicts the ordering of patients’ death times. For
context, a c = 0.5 is the average C-index of a random model, whereas c = 1 is a perfect ranking
of death times. We perform bootstrapping [27] and sample the test set with replacement to obtain
confidence intervals.
Table 1: Experimental Results for All Experiments: C-index (95% Confidence Interval)
Experiment CPH DeepSurv RSF
Simulated Linear 0.773677
(0.772,0.775)
0.774019
(0.772,0.776)
0.764925
(0.763,0.766)
Simulated Non-
linear
0.506951
(0.505,0.509)
0.648902
(0.647, 0.651)
0.645540
(0.643,0.648)
WHAS 0.817620
(0.814, 0.821)
0.862620
(0.859,0.866)
0.893623
(0.891,0.896)
SUPPORT 0.582870
(0.581,0.585)
0.618308
(0.616,0.620)
0.613022
(0.611,0.615)
METABRIC 0.630618
(0.627,0.635)
0.643374
(0.639,0.647)
0.624331
(0.620,0.629)
Simulated Treat-
ment
0.481540
(0.480,0.483)
0.582774
(0.580,0.585)
0.569870
(0.568,0.572)
Rotterdam &
GBSG
0.657750
(0.654, 0.661)
0.668402
(0.665,0.671)
0.651190
(0.648, 0.654)
Treatment recommendations
We determine the recommended treatment for each patient in the test set using DeepSurv and the
RSF. We do not calculate the recommended treatment for CPH; without preselected treatment-
interaction terms, the CPH model will compute a constant recommender function and recommend
the same treatment option for all patients. This would effectively be comparing the survival rates
between the control and experimental groups. DeepSurv and the RSF are capable of predicting an
individual’s risk per treatment because each computes relevant interaction terms. For DeepSurv, we
choose the recommended treatment by calculating the recommender function (Equation 5). Because
the RSF predicts a cumulative hazard for each patient, we choose the treatment with the minimum
cumulative hazard.
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Once we determine the recommended treatment, we identify two subsets of patients: those whose
treatment group aligns with the model’s recommended treatment (Recommendation) and those who
do not undergo the recommended treatment (Anti-Recommendation). We calculate the median sur-
vival time of each subset to determine if a model’s treatment recommendations increase the survival
rate of the patients. We then perform a log-rank test to validate whether the difference between the
two subsets is significant.
Table 2: Experimental Results for Treatment Recommendations: Median Survival Time (months)
Experiment
DeepSurv RSF
Rec Anti-Rec Rec Anti-Rec
Simulated 4.069 2.827 3.116 3.625
Rotterdam &
GBSG
40.099 31.770 36.567 32.394
4.2 Simulated survival data
In this section, we perform two experiments with simulated survival data: one with a linear risk func-
tion and one with a nonlinear (Gaussian) risk function. The advantage of using simulated datasets
is that we can ascertain whether DeepSurv can successfully model the true risk function instead of
overfitting random noise.
For each experiment, we generate a training, validation, and testing set of N = 4000, 1000, 1000
observations respectively. Each observation represents a patient vector with d = 10 covariates,
each drawn from a uniform distribution on [−1, 1). We generate the death time T according to an
exponential Cox model [28]:
T ∼ Exp(λ(t;x)) = Exp(λ0 · eh(x)) (6)
Details of the simulated data generation are found in Appendix C.
In both experiments, the risk function h(x) only depends on two of the ten covariates, and we demon-
strate that DeepSurv discerns the relevant covariates from the noise. We then choose a censoring
time to represent the ‘end of study’ such that about 90 percent of the patients have an observed event
in the dataset.
4.2.1 Linear risk experiment
We first simulate patients to have a linear risk function for x ∈ Rd so that the linear proportional
hazards assumption holds true:
h(x) = x0 + 2x1. (7)
Because the linear proportional hazards assumption holds true, we expect the linear CPH to accu-
rately model the risk function in Equation 7.
Our results (see Table 1) demonstrate that DeepSurv performs as well as the standard linear Cox
regression and better than RSF in predictive ability.
Figure 1 demonstrates how DeepSurv more accurately models the risk function compared to the
linear CPH. Figure 1(a) plots the true risk function h(x) for all patients in the test set. As shown
in Figure 1(b), the CPH’s estimated risk function hˆβ(x) does not perfectly model the true risk for a
patient. In contrast, as shown in Figure 1(c), DeepSurv better estimates the true risk function.
To quantify these differences, Figures 1(d) and 1(e) show that the CPH’s estimated risk has a signif-
icantly larger absolute error than that of DeepSurv, specifically for patients with a high positive risk.
We calculate the mean-squared-error (MSE) between a model’s predicted risk and the true risk val-
ues. The MSEs of CPH and DeepSurv are 20.197 and 0.126, respectively. Even though DeepSurv
and CPH have similar predictive abilities, this demonstrates that DeepSurv is superior than the CPH
at modeling the true risk function of the population.
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(e) |h(x)− hˆθ(x)|
Figure 1: Predicted risk surfaces and errors for the simulated survival data with linear risk function
with respect to a patient’s covariates x0 and x1. 1(a) The true risk h(x) = x0 + 2x1 for each patient.
1(b) The predicted risk surface of hˆβ(x) from the linear CPH model parameterized by β. 1(c) The
output of DeepSurv hˆθ(x) predicts a patient’s risk. 1(d) The absolute error between true risk h(x)
and CPH’s predicted risk hˆβ(x). 1(e) The absolute error between true risk h(x) and DeepSurv’s
predicted risk hˆθ(x).
4.2.2 Nonlinear risk experiment
We set the risk function to be a Gaussian with λmax = 5.0 and a scale factor of r = 0.5:
h(x) = log(λmax) exp
(
−x
2
0 + x
2
1
2r2
)
(8)
The surface of the risk function is depicted in 2(a). Because this risk function is nonlinear, we do not
expect the CPH to predict the risk function properly without adding quadratic terms of the covariates
to the model. We expect DeepSurv to reconstruct the Gaussian risk function and successfully predict
a patient’s risk. Lastly, we expect the RSF and DeepSurv to accurately rank the order of patient’s
deaths.
The CI results in Table 1 shows that DeepSurv outperforms the linear CPH and predicts as well as the
RSF. In addition, DeepSurv correctly learns nonlinear relationships between a patient’s covariates
and their risk. As shown in Figure 2, DeepSurv is more successful than the linear CPH in modeling
the true risk function. Figure 2(b) demonstrates that the linear CPH regression fails to determine the
first two covariates as significant. The CPH has a C-index of 0.506951, which is equivalent to the
performance of randomly ranking death times. Meanwhile, Figure 2(c) demonstrates that DeepSurv
reconstructs the Gaussian relationship between the first two covariates and a patient’s risk.
4.3 Real survival data experiments
We compare the performance of the CPH and DeepSurv on three datasets from real studies: the
Worcester Heart Attack Study (WHAS), the Study to Understand Prognoses Preferences Outcomes
and Risks of Treatment (SUPPORT), and The Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC). Because previous research shows that neural networks do not outper-
form the CPH, our goal is to demonstrate that DeepSurv does indeed have state-of-the-art predictive
ability in practice on real survival datasets.
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(c) DeepSurv hˆθ(x)
Figure 2: Risk surfaces of the nonlinear test set with respect to patient’s covariates x0 and x1. 2(a)
The calculated true risk h(x) (Equation 8) for each patient. 2(b) The predicted risk surface of hˆβ(x)
from the linear CPH model parameterized on β. The linear CPH predicts a constant risk. 2(c) The
output of DeepSurv hˆθ(x) is the estimated risk function.
4.3.1 Worcester Heart Attack Study (WHAS)
The Worcester Heart Attack Study (WHAS) investigates the effects of a patient’s factors on acute
myocardial infraction (MI) survival [29]. The dataset consists of 1,638 observations and 5 features:
age, sex, body-mass-index (BMI), left heart failure complications (CHF), and order of MI (MIORD).
We reserve 20 percent of the dataset as a testing set. A total of 42.12 percent of patients died during
the survey with a median death time of 516.0 days. As shown in Table 1, DeepSurv outperforms the
CPH; however, the RSF outperforms DeepSurv.
4.4 Study to Understand Prognoses Preferences Outcomes and Risks of Treatment
(SUPPORT)
The Study to Understand Prognoses Preferences Outcomes and Risks of Treatment (SUPPORT) is
a larger study that researches the survival time of seriously ill hospitalized adults [30]. The dataset
consists of 9,105 patients and 14 features for which almost all patients have observed entries (age,
sex, race, number of comorbidities, presence of diabetes, presence of dementia, presence of cancer,
mean arterial blood pressure, heart rate, respiration rate, temperature, white blood cell count, serum’s
sodium, and serum’s creatinine). We drop patients with any missing features and reserve 20 percent
of the dataset as a testing set. A total of 68.10 percent of patients died during the survey with a
median death time of 58 days.
As shown in Table 1, DeepSurv performs as well as the RSF and better than the CPH with a larger
study. This validates DeepSurv’s ability to predict the ranking of patient’s risks on real survival data.
4.4.1 Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) uses gene and
protein expression profiles to determine new breast cancer subgroups in order to help physicians
provide better treatment recommendations.
The METABRIC dataset consists of gene expression data and clinical features for 1,980 patients, and
57.72 percent have an observed death due to breast cancer with a median survival time of 116 months
[31]. We prepare the dataset in line with the Immunohistochemical 4 plus Clinical (IHC4+C) test,
which is a common prognostic tool for evaluating treatment options for breast cancer patients [32].
We join the 4 gene indicators (MKI67, EGFR, PGR, and ERBB2) with the a patient’s clinical features
(hormone treatment indicator, radiotherapy indicator, chemotherapy indicator, ER-positive indicator,
age at diagnosis). We then reserved 20 percent of the patients as the test set.
Table 1 shows that DeepSurv performs better than both the CPH and RSF. This result demonstrates
not only DeepSurv’s ability to model the risk effects of gene expression data but also shows the
potential for future research of DeepSurv as a comparable prognostic tool to common medical tests
such as the IHC4+C.
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4.5 Treatment recommender system experiments
In this section, we perform two experiments to demonstrate the effectiveness of DeepSurv’s treat-
ment recommender system. First, we simulate treatment data by including an additional covariate
to the simulated data from Section 4.2.2. Second, after demonstrating DeepSurv’s modeling and
recommendation capabilities, we apply the recommender system to a real dataset used to study the
effects of hormone treatment on breast cancer patients. We show that DeepSurv can successfully
provide personalized treatment recommendations. We conclude that if all patients follow the net-
work’s recommended treatment options, we would gain a significant increase in patients’ lifespans.
4.5.1 Simulated treatment data
We uniformly assign a treatment group τ ∈ {0, 1} to each simulated patient in the dataset. All of
the patients in group τ = 0 were ‘unaffected’ by the treatment (e.g. given a placebo) and have a
constant risk function h0(x). The other group τ = 1 is prescribed a treatment with Gaussian effects
(Equation 8) and has a risk function h1(x) with λmax = 10 and r = 0.5.
Figure 3 illustrates the network’s success in modeling both treatments’ risk functions for patients.
Figure 3(a) plots the true risk distribution h(x). As expected, Figure 3(b) shows that the network
models a constant risk for a patient in treatment τ = 0, independent of a patient’s covariates. Figure
3(c) shows how DeepSurv models the Gaussian effects of a patient’s covariates on their treatment
risk. To further quantify these results, Table 1 shows that DeepSurv has the largest concordance
index. Because the network accurately reconstructs the risk function, we expect that it will provide
accurate treatment recommendations for new patients.
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(c) DeepSurv hˆ1(x)
Figure 3: Treatment Risk Surfaces as a function of a patient’s relevant covariates x0 and x1. 3(a)
The true risk h1(x) if all patients in the test set were given treatment τ = 1. We then manually set all
treatment groups to either τ = 0 or τ = 1. 3(b) The predicted risk hˆ0(x) for patients with treatment
group τ = 0. 3(c) The network’s predicted risk hˆ1(x) for patients in treatment group τ = 1.
In Figure 4, we plot the Kaplan-Meier survival curves for both the Recommendation and Anti-
Recommendation subset for each method. Figure 4(a) shows that the survival curve for the Rec-
ommendation subset is shifted to the right, which signifies an increase in survival time for the pop-
ulation following DeepSurv’s recommendations. This is further quantified by the median survival
times summarized in Table 2. The p-value of DeepSurv’s recommendations is less than 1e−5, and
we can reject the null hypothesis that DeepSurv’s recommendations would not affect the popula-
tion’s survival time. As shown in Table 2, the subset of patients that follow RSF’s recommendations
have a shorter survival time than those who do not follow RSF’s recommended treatment. There-
fore, we could take the RSF’s recommendations and provide the patients with the opposite treatment
option to increase median survival time; however, Figure 4(b) shows that that improvement would
not be statistically valid. While both methods of DeepSurv and RSF are able to compute treatment
interaction terms, DeepSurv is more successful in recommending personalized treatments.
4.5.2 Rotterdam & German Breast Cancer Study Group (GBSG)
We first train DeepSurv on breast cancer data from the Rotterdam tumor bank [33]. and construct a
recommender system to provide treatment recommendations to patients from a study by the German
Breast Cancer Study Group (GBSG) [34]. The Rotterdam tumor bank dataset contains records
for 1,546 patients with node-positive breast cancer, and nearly 90 percent of the patients have an
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Figure 4: Kaplan-Meier estimated survival curves with confidence intervals (α = .05) for the pa-
tients who were given the treatment concordant with a method’s recommended treatment (Recom-
mendation) and the subset of patients who were not (Anti-Recommendation). We perform a log-rank
test to validate the significance between each set of survival curves.
observed death time. The testing data from the GBSG contains complete data for 686 patients (56
percent are censored) in a randomized clinical trial that studied the effects of chemotherapy and
hormone treatment on survival rate. We preprocess the data as outlined by [35].
We first validate DeepSurv’s performance against the RSF and CPH baseline. We then plot the two
survival curves: the survival times of those who followed the recommended treatment and those who
did not. If the recommender system is effective, we expect the population with the recommended
treatments to survive longer than those who did not take the recommended treatment.
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Figure 5: Kaplan-Meier estimated survival curves with confidence intervals (α = .05) for the pa-
tients who were given the treatment concordant with a method’s recommended treatment (Recom-
mendation) and the subset of patients who were not (Anti-Recommendation). We perform a log-rank
test to validate the significance between each set of survival curves.
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Table 1 shows that DeepSurv provides an improved predictive ability relative to the CPH and RSF.
In Figure 5, we plot the Kaplan-Meier survival curves for both the Recommendation subset and
the Anti-Recommendation subset for each method. Figure 5(a) shows that the survival curve for
DeepSurv’s Recommendation subset is statistically significant from the Anti-recommendation sub-
set, and Table 2 shows that DeepSurv’s recommendations increase the median survival time of the
population. Figure 5(b) demonstrates that RSF is unable to provide significant treatment recommen-
dations, despite an increase in median survival times (see Table 2). The results of this experiment
demonstrate not only DeepSurv’s superior modeling capabilities but also validate DeepSurv’s ability
in providing personalized treatment recommendations on real clinical data. Moreover, we can train
DeepSurv on survival data from one clinical study and transfer the learnings to provide personalized
treatment recommendations to a different population of breast cancer patients.
5 Conclusion
In conclusion, we demonstrated that the use of deep learning in survival analysis allows for: (i)
higher performance due to the flexibility of the model, and (ii) effective treatment recommenda-
tions based on the predicted effect of treatment options on an individual’s risk. We validated that
DeepSurv predicts patients’ risk mostly as well as or better than other linear and nonlinear sur-
vival methods. We experimented on increasingly complex survival datasets and demonstrated that
DeepSurv computes complex and nonlinear features without a priori selection or domain expertise.
We then demonstrated that DeepSurv is superior in predicting personalized treatment recommenda-
tions compared to the state-of-the-art survival method of random survival forests. We also released
a Python module that implements DeepSurv and scripts for running reproducible experiments in
Docker, see https://github.com/jaredleekatzman/DeepSurv for more details. The success of Deep-
Surv’s predictive, modeling, and recommending abilities paves the way for future research in deep
neural networks and survival analysis. DeepSurv can lead to various extensions, such as the use
of convolution neural networks to predict risk with medical imaging. With more research at scale,
DeepSurv has the potential to supplement traditional survival analysis methods and become a stan-
dard method for medical practitioners to study and recommend personalized treatment options.
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Appendix
A Experimental Details
We run all linear CPH regression, Kaplan-Meier estimations, c-index statistics, and log-rank tests
using the Lifelines Python package. DeepSurv is implemented in Theano with the Python package
Lasagne. We use the R package randomForestSRC to fit RSFs. All experiments are run using
Docker containers such that the experiments are easily reproducible. We use the FloydHub base
image for the DeepSurv docker container.
The hyper-parameters of the network include: the depth and size of the network, learning rate, `2
regularization coefficient, dropout rate, exponential learning rate decay constant , and momentum.
We run the Random hyper-parameter optimization search as proposed in [25] using the Python pack-
age Optunity. We use the Sobol solver [36, 37] to sample each hyper-parameter from a predefined
range and evaluate the performance of the configuration using k-means cross validation (k = 3).
We then choose the configuration with the largest validation C-index to avoid models that overfit.
The hyper-parameters we use in all experiments are summarized in Appendix A.1.
A.1 Model Hyper-parameters
We tune DeepSurv’s hyper-parameters by running a random hyper-parameter search using the
Python package Optunity. The table below summarizes the hyper-parameters we use for each ex-
periment’s DeepSurv network.
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Table 3: DeepSurv’s Experimental Hyper-parameters
Hyper-parameter Sim Linear Sim Nonlinear WHAS SUPPORT METABRIC Sim Treatment GBSG
Optimizer sgd sgd adam adam adam adam adam
Activation SELU ReLU ReLU SELU SELU SELU SELU
# Dense Layers 1 3 2 1 1 1 1
# Nodes / Layer 4 17 48 44 41 45 8
Learning Rate (LR) 2.922e−4 3.194e−4 0.067 0.047 0.010 0.026 0.154
`2 Reg 1.999 4.425 16.094 8.120 10.891 9.722 6.551
Dropout 0.375 0.401 0.147 0.255 0.160 0.109 0.661
LR Decay 3.579e−4 3.173e−4 6.494e−4 2.573e−3 4.169e−3 1.636e−4 5.667e−3
Momentum 0.906 0.936 0.863 0.859 0.844 0.845 0.887
We applied inverse time decay to the learning rate at each epoch:
decayed LR :=
LR
1 + epoch · lr decay rate . (9)
B CPH Recommender Function
Let each patient in the dataset have a set of n features xn, in which one feature is a treatment variable
x0 = τ . The CPH model estimates the risk function as a linear combination of the patient’s features
hˆβ(x) = β
Tx = β0τ + β1x1 + ... + βnxn. When we calculate the recommender function for
the CPH model, we show that the model returns a constant function independent of the patient’s
features:
recij(x) = log
( λ(t;x|τ = i)
λ(t;x|τ = j)
)
= log
(λ0(t) · eβ0i+β1x1+...+βnxn
λ0(t) · eβ0j+β1x1+...+βnxn
)
= log
(
eβ0i+β1x1+...+βnxn−(β0j+β1x1+...+βnxn)
)
= β0i− β0j
= β0(i− j).
(10)
The CPH will recommend all patients to choose the same treatment option based on whether the
model calculates the weight β0 to be positive or negative. Thus, the CPH would not be provid-
ing personalized treatment recommendations. Instead, the CPH determines whether the treatment
is effective and, if so, then recommending it to all patients. In an experiment, when we calculate
which patients took the CPH’s recommendation, the Recommendation and Anti-Recommendation
subgroups will be equal to the control and treatment groups. Therefore, calculating treatment rec-
ommendations using the CPH provides little value to the experiments in terms of comparing the
models’ recommendations.
C Simulated Data Generation
Each patient’s baseline information x is drawn from a uniform distribution on [−1, 1)d. For datasets
that also involve treatment, the patient’s treatment status τx is drawn from a Bernoulli distribution
with p = 0.5.
The Cox proportional hazard model assumes that the baseline hazard function λ0(t) is shared across
all patients. The initial death time is generated according to an exponential random variable with a
mean µ = 5, which we denote u ∼ Exp(5). The individual death time is then generated by
T =
u
eh(x)
, when there is no treatment variable,
T =
u
eτxh(x)
, when there is a treatment variable.
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These times are then right censored at an end time to represent the end of a trial. The end time T0 is
chosen such that 90 percent of people have an observed death time.
Because we cannot observe any T beyond the end time threshold, we denote the final observed
outcome time
Z = min(T, T0).
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